Abstract

Background: Methotrexate (MTX) is an anti-metabolite drug widely used in treatment of neoplastic disorders, rheumatoid arthritis and psoriasis. The ester derivative, ethyl pyruvate (EP) is stable in solution and should function as an antioxidant and energy precursor. This study was conducted to evaluate the protective role of EP on sperm parameters, testosterone level and malondialdehyde (MDA) production in mice treated with MTX.

Methods: 32 adult male NMRI mice weighing 26±2 g were divided into 4 groups. Group 1 received 0.1 ml/mice/day of distilled water intraperitoneally for 30 days (ip). Group 2 was treated with methotrexate at a dose of 20 mg/kg once a week (ip) for 30 days. Group 3 was treated with ethyl pyruvate at a dose of 40 mg/kg/daily (ip) for 30 days. Group 4 was treated with methotrexate (20 mg/kg) once a week simultaneously with ethyl pyruvate 40 mg/kg for 30 days. The results were analyzed by one-way ANOVA. A p<0.05 was considered to be significant.

Results: The results showed significant (p<0.05) decrease in sperm count and sperm motility as well as testosterone concentration while sperm with damaged DNA and MDA concentration in mice treated with MTX in comparison with control and MX+EP groups increased significantly (p<0.05). Instead, MTX+EP group caused partial amelioration in all parameters mentioned above.

Conclusion: Based on the present study, it can be concluded that MTX induced toxicity in sperm parameters and serum level of testosterone and increased MDA level. EP with its antioxidant properties could be administrated during treatment with MTX due to its protective effects on sperm parameters, plasma testosterone levels and lipid peroxidation.

Keywords: Ethyl pyruvate, Malondialdehyde, Methotrexate, Mice, Spermatozoa, Testosterone.


Introduction

In recent years, natural antioxidant products have gained attention based on their protective effects against drug-induced toxicities especially whenever free radical generation is involved (1). The intake in human diet of antioxidant compounds or compounds that ameliorate or enhance the biological antioxidant mechanisms, can prevent and in some cases help in the treatment of some oxidative-related disorders and organ toxicity events (2). Pyruvate is a key intermediate metabolite of glucose and a potent antioxidant and free radical scavenger (3).

Pyruvate has been shown to afford protection in numerous in vitro and in vivo models including oxidant mediated cellular ones or organ system injury (4). It is a well-known scavenger of hydro-
gen peroxide and superoxide radicals (5, 6). In the presence of hydrogen peroxide, pyruvate will de-
carboxylate to yield acetate, water and carbon di-
oxide (7). Unfortunately, the usefulness of py-
rutate as a therapeutic agent is diminished by its
very poor stability in solution (8). Ethyl pyruvate
(EP), a simple aliphatic ester derived from pyruvic
acid, is safer and more stable than pyruvate (8).
Like pyruvate, ethyl pyruvate could also rapidly
and stoichiometrically scavenge hydrogen perox-
ide. Supporting this idea, some studies show that
treatment with EP provides biochemical evidence
for a decrease in oxidative stress both in vitro and
in vivo and in models of ischemia/reperfusion in-
jury (5, 9).

Chemotherapy is one of the most effective meth-
ods for the treatment of cancer, but is often associ-
ated with several short and long-term toxicities
(10). MTX is a widely used anti-cancer drug and a
well-known immunosuppressant introduced for
therapeutic application in 1950 (11). It is used
against a broad range of neoplastic disorders in-
cluding acute lymphoblastic leukemia, non-
Hodgkin’s lymphoma, breast cancer and testicular
tumours (12, 13). Further, it is effective for the
treatment of psoriasis, rheumatoid arthritis and
different immunosuppressive propose (14, 15).

The basic principle of its therapeutic efficacy is
related to the inhibition of dihydrofolate reduc-
tase, a key enzyme in the folic acid metabolism,
which converts dihydrofolate to tetrahydrofolate
acid. The perturbation in the folic acid metabolism
leads to depletion of nucleotide precursors like
thymidylates and purines, which in turn inhibits
DNA, RNA and protein synthesis (16, 17). MTX
has narrow therapeutic index and its toxicity has
been reported in various organ systems including
gastrointestinal, hematologic and central nervous
system. Methotrexate may have an effect on hypo-
thalamic-pituitary-gonadal axis or a direct toxic
effect on the gonads (18). Studies in animals have
shown altered spermatogenesis, cytotoxicity and
degeneration of spermatocytes, Sertoli cells, and
Leydig cells (19, 20).

Methods

Animals: Thirty two adult male NMRI mice (8-
10 weeks old) weighing 26±2 g were purchased
from animal house of faculty of science Urmia
University. All animals were kept under con-
trolled environmental conditions at room tempera-
ture (22±2°C) with humidity of 50±10% and a
12/12 hr photoperiod. The animals were provided
with standard diet pellets and water ad libitum.

Experimental design: Animals were randomly di-
vided into four groups, containing 8 mice in each
Group 1 (control) received distilled water
0.1 ml/mice/day (ip) for 30 day. Group 2 (MTX)
received methotrexate at a dose of 20 mg/kg once
a week (ip) for 30 days. Group 3 (EP) received
ethyl pyruvate at a dose of 40 mg/kg/daily (ip) for
30 days. Group 4 (MTX+EP) received methotrex-
ate at a dose of 20 mg/kg once a week (ip) con-
comitant with ethyl pyruvate administration at a
dose of 40 mg/kg over a week.

Sperm collection: 24 hr after the end of the treat-
ment period, animals were sacrificed by disloca-
tion of cervical vertebrae. The caudal epididymis
was removed after sacrificing the animals and
placed into 1 ml of HTF medium with 4 mg/ml of
Bovine Serum Albumin, then minced into small
pieces to allow the sperm to swim out and incu-
bated at 37°C/5% CO₂ for 30 min.

Sperm count: The obtained sperm suspension was
centrifuged at 1000 rpm for 5 min. After centrifu-
gation, 10 μl of the supernatant was taken and the
epididymal sperm count was determined using
Neubauerhemocytometer (21).

Sperm viability: Sperm viability was evaluated as
follows. 20 μl of 0.05% Eosin Y -Nigrosin were
added into an equal volume of sperm suspension.
After 2 min of incubation at room temperature,
slides were viewed by light microscope with
magnification of ×400. Dead sperm appeared to
be pink and live sperm were not stained. In each
sample, 400 sperm were counted and viability per-
centages were calculated (22).

Sperm motility: The motility was determined by
placing 10 μl of the sperm suspension on a clean
pre-warmed microscopic slide, covered with a
cover-slip and examined using a light microscope
at 400× magnification (Nikon Labophot 2) equip-
ped with a heated stage (37°C). The motility of
each spermatozoon was graded as "RPFM" (rapid
progressive forward movement), "SPFM" (slowly
progressive forward movement) "RM" (residual
motion) and "ML" (motionless) and percentages
of motile and immotile sperm were obtained (23).

Acridine Orange (AO) staining: Sperm DNA frag-
mentation has now become a new biomarker for
male infertility diagnosis (24). Acridine Orange
(AO) staining is used, after challenge at a low pH,
to distinguish between denatured, single stranded,
native, and double-stranded DNA regions in
sperm chromatin (25). The results showed the cytogram patterns of the fluorescence intensity of denatured DNA (red) and native DNA (green). Thick smears were placed in Carnoy’s fixative (methanol/ acetic acid 1:3) for 2 hr for fixation (26). The slides were removed from the fixative and allowed to dry for a few minutes. After 5 min at laboratory temperature, the sperm were stained with stock solution consisting of 1 mg of AO in 1000 ml of distilled water and stored in the dark at 4 °C. The staining solution was prepared as follows. 10 ml of the stock solution was added to 40 ml of 0.1 M citric acid and 2.5 ml of 0.3 M Na2HPO4 · 7H2O (28). After staining for 5 min, the slides were rinsed with deionized water. The sperm were analyzed by fluorescent light microscopy. Red and green sperm could be observed, green sperm were classified as normal DNA and yellow to red sperm were classified as damaged DNA (26).

**Acidic Aniline Blue Staining (AABS):** During histone replacement with protamines and chromatin condensation in spermatogenesis, normal sperm do not stain with aniline blue, but sperm with defective density or immature sperm absorb the stain (28). Sperm samples were air-dried and fixed for 30 min in 3% glutaraldehyde in phosphate buffered saline (pH=7.2). Each smear was stained with 5% acidic aniline blue stain (5 g aniline blue (Sigma-Aldrich, USA), 4% acetic acid in double distilled water, pH=3.5 for 5 min). At least 200 spermatozoa under light microscopy (Olympus Co, Tokyo, Japan) were counted in each slide (29).

**Measurement of Malondialdehyde (MDA):** In order to do this, 300 μl of 10% trichloroacetic acid was added to 150 μl of the sample and centrifuged at 1,000 rpm for 10 min at 4°C. 300 μl of supernatant was transferred to a test tube with 300 μl of 67% thiobarbituric acid and incubated at 100°C for 25 min. 5 min after cooling the solution, a pink color appeared because of MDA-TBA reaction and was evaluated using a spectrophotometer at a wavelength of 535 nm (30).

**Testosterone assay:** After collecting blood, samples were centrifuged to isolate serum and kept at −80°C until biochemical analysis with immuno-radiometric technique (WHO/Sigma Asso-RTGC-768/98) for testosterone measurement.

**Statistical analysis:** Results were shown as mean± standard error of mean (S.E.M.) for each group. For comparison between the groups, the results were analyzed by SPSS 16 software, using one-way ANOVA followed by a Bonferroni post hoc test. A p<0.05 was considered significant.

**Results**

**Sperm parameters:** The results revealed that sperm count decreased significantly (p<0.05) in methotrexate group in comparison with the control group. Ethyl pyruvate+methotrexate group revealed significant enhancement (p<0.05) in sperm count which are presented in table 1. There was no significant (p>0.05) difference in sperm maturity among groups. Treatment with anti-neoplastic drug (MTX) caused a significant decrease in viability and an increase in sperm with damaged DNA compared with the control group while Ethyl pyruvate caused improvement in viability and DNA fragmentation in MTX+EP group (Figure1, 2, 3; Table1).

![Figure 1. MTX+EP group, live sperm; 1: with uncoloured head and dead sperm; 2: with red head (Eosin Y Nigrosin ×1000)](image1)

![Figure 2. EP group: sperm head with mature nuclei is light blue; 1: and sperm head containing immature nuclear chromatin is dark blue; 2: (Aniline blue ×1000)](image2)

![Figure 3. MTX+EP group: sperm with normal DNA integrity had green fluorescence, and those with diminished DNA integrity had orange-red staining (Acridine orange ×400)](image3)
In table 2, we can see that regarding sperm motility, compared with the control group, RPFM decreased significantly (p<0.05) in methotrexate group. However, Ethyl pyruvate caused an increase in RPFM in MTX+EP group which was significantly (p<0.05) higher compared with the MTX group. SPFM results indicated that the difference between groups was not significant. RM and ML in MTX treatment group increased significantly (p<0.05). MTX treatment in EP supplemented animals showed a significant reduction (p<0.05) in RM and ML compared with MTX group alone (Table 2).

**Biochemical results:** The results of biochemical analyses were shown in table 3. Briefly, the level of MDA, a major degradation product of lipid peroxidation, was significantly increased in MTX treated mice compared with the control group (p<0.05). There was a significant restoration in MDA level in the groups that received EP treatment with MTX (p<0.05).

The level of testosterone was found to be significantly lower in MTX-treated group when compared with other groups (p<0.005). Ethyl pyruvate administration, after MTX, caused significant increase in testosterone concentrations when compared with MTX and control group alone (p<0.05). On the other hand, EP+MTX group testosterone level was similar to the control group.

**Table 1.** The effect of methotrexate and Ethyl pyruvate on wperm count, sperm viability, sperm maturity and DNA damage in mice (M±SE)

<table>
<thead>
<tr>
<th>Group</th>
<th>Sperm count (×10⁶)</th>
<th>Sperm viability (%)</th>
<th>Sperm maturity (%)</th>
<th>Acridine orange+ (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>26.66±1.87</td>
<td>88.00±2.88</td>
<td>89.00±0.57</td>
<td>5.73±0.29</td>
</tr>
<tr>
<td>MTX</td>
<td>7.50±1.15 a</td>
<td>52.33±2.33 a</td>
<td>90.33±1.76</td>
<td>12.66±1.4 a</td>
</tr>
<tr>
<td>EP</td>
<td>25.94±0.81 b</td>
<td>81.66±2.33 ab</td>
<td>90.33±0.33</td>
<td>6.26±0.52 b</td>
</tr>
<tr>
<td>MTX+EP</td>
<td>15.16±1.74 ab</td>
<td>63.88±4.13 ab</td>
<td>96.00±1.15</td>
<td>7.00±0.75 b</td>
</tr>
</tbody>
</table>

a: different significant (p<0.05) compared with control group; b: different significant (p<0.05) compared with MTX group

**Table 2.** Effect of EP on sperm motility in mice treated with MTX (M±SE)

<table>
<thead>
<tr>
<th>Group</th>
<th>Sperm motility (RPFM) (%)</th>
<th>Sperm motility (SPFM) (%)</th>
<th>Sperm motility (RM) (%)</th>
<th>Sperm motility (ML) (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>66.12±0.54</td>
<td>14.28±1.00</td>
<td>12.10±1.76</td>
<td>11.51±1.61</td>
</tr>
<tr>
<td>MTX</td>
<td>26.10±1.82 a</td>
<td>13.73±1.89</td>
<td>39.57±2.60 a</td>
<td>20.59±0.68 a</td>
</tr>
<tr>
<td>EP</td>
<td>61.30±2.13 b</td>
<td>13.53±3.37</td>
<td>17.23±3.51 b</td>
<td>7.93±1.30 b</td>
</tr>
<tr>
<td>MTX+EP</td>
<td>49.35±2.92 ab</td>
<td>16.80±1.10</td>
<td>21.58±1.31 ab</td>
<td>11.83±1.24 b</td>
</tr>
</tbody>
</table>

a: different significant (p<0.05) compared with control group; b: different significant (p<0.05) compared with MTX group

**Table 3.** Comparison of the effect of EP on testosterone level and lipid peroxidation caused by MTX (M±SE)

<table>
<thead>
<tr>
<th>Group</th>
<th>MDA (µmol/gr tissue)</th>
<th>Testosterone (ng/ml)</th>
</tr>
</thead>
<tbody>
<tr>
<td>control</td>
<td>165.66±4.63</td>
<td>0.42±0.02</td>
</tr>
<tr>
<td>MTX</td>
<td>357.33±4.09 a</td>
<td>0.19±0.02 a</td>
</tr>
<tr>
<td>EP</td>
<td>187.00±9.53 a</td>
<td>0.58±0.03 ab</td>
</tr>
<tr>
<td>MTX+EP</td>
<td>203.66±20.4 ab</td>
<td>0.49±0.04 b</td>
</tr>
</tbody>
</table>

a: different significant (p<0.05) compared with control group; b: different significant (p<0.05) compared with MTX group

**Discussion**

Although most of chemotherapeutic agents are mutagenic and carcinogenic (31), they are extensively used for the treatment of various types of cancers, as at times, they cure the disease or at least increase the life expectancy of cancer patients (32).

Also, research shows that there is a significant relationship between ROS production and apoptosis which cause DNA damage in sperm. We reached the same results in our AO assays, observing that MTX caused a significant increase in DNA fragmentation (p<0.05).

Sperm counts are a crude measure of fertility (33, 34). In this study, we observed that sperm count and viability were reduced significantly in MTX-treated animals. Decrease in sperm count often results due to the interference in the spermatogenesis process and the elimination of sperm cells at different stages of development (34, 35).

Sperm motility is also as important as the counts in respect to male fertility. We found that MTX-treated mice had less sperm motility. The significant reduction in sperm motility may be due to the...
status of oxidative stress observed during MTX administration which is accompanied by increased lipid peroxidation in various tissues (36, 37). Lipid peroxidation products in testis were determined by measuring malondialdehyde (MDA). Malondialdehyde is a good indicator of the degree of lipid peroxidation, which in our study, the level of MDA in MTX-treated rats was significantly higher than the control group (p<0.05). This finding was in agreement with several reports demonstrating MTX-induced oxidative stress in tissues (38, 39).

Whereas EP has been shown to inhibit lipid peroxidation, it is a marker for oxidative stress both in in vitro (40) and in vivo (41) conditions. Tsung et al. have recently shown that EP decreases hepatic lipid peroxidation (42). Interestingly, in our combined EP-MTX treated groups, we observed that MDA value was significantly lower than that of MTX-treated group. Our results in MDA measurement are in agreement with previous studies (41, 43).

Recent advances showed that ROS and hydrogen peroxides are linked with the development of several pathological processes associated with chemotherapy, including adverse effects of anti-tumor drugs. It may be suggested that the cells could be more sensitive to ROS, which subsequently results in reduction of effectiveness of the antioxidant enzyme defense system (44, 45).

On the other hand, EP is unlikely to be harmful to humans, given its close similarity to an endogenous metabolite, its safety profiles in animals, and its common use as a food supplement. EP can react with ROS both via oxidative carboxylation and via formation of hydroxylated adducts at the 3-carbon (46).

In the present study, EP was administered in the form of antioxidant and by a dose of 40 mg/kg which because of its antioxidant and free radical scavenging properties could reduce the side effects of MTX such as DNA damage, low sperm count and decreased viability and motility of sperm in MTX treated mice.

**Conclusion**

This study clearly showed that MTX treatment in mice induced testicular injury as is evident from the decreased count, viability, motility of sperm and sperm DNA damage. Treatment with EP significantly ameliorated the toxic side effects of MTX. Thus, the results of the present study encourage new experimental and clinical studies to evaluate the efficacy of EP as an adjunctive agent to ameliorate the toxic effects of anti-neoplastic drugs that cause oxidative tissue injury.

**Acknowledgement**

The authors would like to thank Mr. Eskandar Poorgadim for technical assistance and laboratory equipment supply.

**Conflict of Interest**

There was no conflict of interest between authors.

**References**


24. Carrell DT, Emery BR, Hammoud S. Altered protamine expression and diminished spermatogene-


36. Tabassum H, Parvez S, Rehman H, Dev Banerjee B, Siemen D, Raisuddin S. Nephrotoxicity and its prevention by taurine in tamoxifen induced oxida-

Atashfaraz E, et al.
Effects of EP on Reproductive Toxicity of MTX

41. Tawadrous ZS, Delude RL, Fink MP. Resuscitation from hemorrhagic shock with Ringer’s ethyl pyruvate solution improves survival and amelio-